Twist Bioscience reported fiscal second-quarter revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking its 13th straight quarter of sequential growth.
The company’s DNA synthesis and protein solutions business generated $53.3 million, a 28% increase from $41.6 million in the prior-year quarter and 4% higher than the first quarter’s $51.1 million. NGS applications revenue rose 12% to $57.4 million from $51.1 million a year ago and climbed 9% sequentially from $52.6 million.
Gross margin improved to 51.6% from 49.6% in the same quarter last year. Cost of revenues increased to $53.6 million from $46.8 million.
Research and development spending fell to $19.7 million from $23.9 million, while selling, general and administrative expenses rose to $76.1 million from $63.7 million. Twist recorded $7.2 million in litigation settlement costs in the quarter tied to a securities class action settlement in principle of about $17.1 million.
Net loss widened to $44.0 million, or $0.71 per share, from $39.3 million, or $0.66 per share, a year earlier. Adjusted EBITDA improved to a loss of $13.3 million from a loss of $14.8 million.
The company ended the quarter with about $172 million in cash, cash equivalents and short-term investments.
Operationally, Twist shipped products to about 2,583 customers, up from about 2,431 a year earlier, and physically shipped about 300,000 genes, compared with about 227,000 in the prior-year quarter.
Twist raised fiscal 2026 revenue guidance to $442 million to $447 million and reiterated its target of adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. Following these announcements, the company's shares moved 3.55%, and are now trading at a price of $60.94. Check out the company's full 8-K submission here.
